TransEnterix Announces First Radical Hysterectomy Performed with Senhance™ Surgical Robot

Surgery marks expanded use of the Senhance in Gynecologic Oncology

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE MKT: TRXC), a medical device company that is
pioneering the use of robotics to improve minimally invasive surgery,
today announced that the first radical hysterectomy for cervical cancer
utilizing its Senhance surgical robot was performed by gynecologic
surgeon Dr. Salvatore Gueli Alletti, a member of Professor Giovanni
Scambia’s team, at the Policlinico A. Gemelli Foundation in Rome, Italy.

“This is an exciting development in the minimally invasive surgical
field. The Senhance system was successfully utilized to perform a
radical hysterectomy with bilateral pelvic lymphadenectomy,” said Dr.
Gueli Alletti. ”This is an extensive oncological dissection, and the
system’s precision, camera control, ergonomics and haptics were
important benefits to help perform this operation safely and
effectively. I strongly believe that the Senhance is a promising
technology in complex gynecologic oncology.”

A radical hysterectomy is performed for early stage cervical cancer and
involves the dissection and removal of all the uterus and parametria,
ovaries, fallopian tubes and the upper portion of the vagina. The
operation is a major cancer operation which includes an extensive pelvic
lymph node dissection.

About TransEnterix

TransEnterix is a medical device company that is pioneering the use of
robotics to improve minimally invasive surgery by addressing the
clinical and economic challenges associated with current laparoscopic
and robotic options. The company is focused on the commercialization of
the Senhance Surgical Robotic System, a multi-port robotic system that
brings the advantages of robotic surgery to patients while enabling
surgeons with innovative technology such as haptic feedback and eye
sensing camera control. The company is also developing the SurgiBot™
System, a single-port, robotically enhanced laparoscopic surgical
platform. The Senhance Surgical Robotic System has been granted a CE
Mark but is not currently available for sale in the United States. For
more information, visit the TransEnterix website at

Forward Looking Statements

This press release includes statements relating to The Senhance™
Surgical Robotic System and the SurgiBot™ System and our current
regulatory and commercialization plans for these products. These
statements and other statements regarding our future plans and goals
constitute “forward looking statements” within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, and are intended to qualify for the safe harbor
from liability established by the Private Securities Litigation Reform
Act of 1995. Such statements are subject to risks and uncertainties that
are often difficult to predict, are beyond our control and which may
cause results to differ materially from expectations, including whether
the Senhance system
is a promising technology in complex
gynecologic oncology. For a discussion of the risks and uncertainties
associated with TransEnterix’s business, please review our filings with
the Securities and Exchange Commission (SEC), including our Annual
Report on Form 10-K filed on March 3, 2016 and our other filings we make
with the SEC. You are cautioned not to place undue reliance on these
forward looking statements, which are based on our expectations as of
the date of this press release and speak
only as of the
origination date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise.


For TransEnterix, Inc.
Investor Contact:
Mark Klausner,
+1 443-213-0501

(For EU) Conrad Harrington, +44 (0)20 3178 8914
US) Hannah Dunning, +1 415-618-8750